{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:44:58Z","timestamp":1777884298476,"version":"3.51.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR 203339"],"award-info":[{"award-number":["NIHR 203339"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patient and Public Involvement and Engagement (PPIE) is advocated in Patient Reported Outcome (PRO) research, but implementation remains inconsistent and often suboptimal. Many barriers exist, including a lack of understanding about how to apply the principles of PPIE in practice. This paper offers an example of how PPIE can be meaningfully integrated into the development of a digital PRO system within the complex and rapidly evolving field of advanced therapies. The aims are to offer practical insights about how PPIE was conceptualised and operationalised in the context of this study, and use the lessons learned to inform future PPIE strategies for PRO research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Co-produced strategy and delivery plans for PPIE were developed by stakeholders, including patients, carers and members of the public, and drawing on national standards and best practice guidelines. This was followed by activities to recruit additional Patient and Public Partners, provide training, identify opportunities for PPIE and map these to key decision points in the research plan. The success of these strategies and activities was evaluated using a range of reflective and assessment methods, in which personal experiences and formal feedback were combined to assess impact and identify areas for improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evaluation revealed that PPIE was successfully integrated across project management, study conduct, and dissemination, generating both research value and personal benefits. However, several conceptual, methodological, and practical challenges were encountered. Three key themes emerged: (i) the challenges of distinguishing between research and PPIE in PRO studies (ii) the factors that shape meaningful PPIE and research impact and (iii) areas for improvement. Early planning, finding the right people, and working co-productively were identified as critical facilitators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Integrating excellent PPIE is achievable in PRO research, even in challenging contexts that involve life-threatening conditions and complex emerging therapies. Although barriers exist, our experience suggests many can be addressed and several actionable recommendations and resources are offered to strengthen PPIE in future PRO research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01036-x","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:25:25Z","timestamp":1774340725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The PRO-CAR-T\u2122 study: achieving excellence in patient and public involvement and engagement"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-8595","authenticated-orcid":false,"given":"Karen L.","family":"Shaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olalekan L.","family":"Aiyegbusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Chakera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronjon","family":"Chakraverty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Chatterley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foram","family":"Khatsuria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"McMullan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Devin","family":"Peipert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lester","family":"Pyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladyslava","family":"Yarosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie J.","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"1036_CR1","unstructured":"National Institute for Health and Care Research (NIHR) (2021) Briefing notes for researchers - public involvement in NHS, health and social care research. https:\/\/www.nihr.ac.uk\/documents\/briefing-notes-for-researchers-public-involvement-in-nhs-health-and-social-care-research\/27371. Accessed 20 March 2025"},{"key":"1036_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/jmp\/jhad024","volume":"48","author":"L Frith","year":"2023","unstructured":"Frith L (2023) Democratic Justifications for Patient Public Involvement and Engagement in Health Research: An Exploration of the Theoretical Debates and Practical Challenges. J Med Philos 48:400\u2013412. https:\/\/doi.org\/10.1093\/jmp\/jhad024","journal-title":"J Med Philos"},{"key":"1036_CR3","unstructured":"US Food and Drug Administration (2009) Patient-reported outcome measures: use in medical product development to support labeling claims. Accessed 20 March 2025"},{"key":"1036_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/d41573-023-00031-x","volume":"22","author":"OL Aiyegbusi","year":"2023","unstructured":"Aiyegbusi OL, Cruz Rivera S, Oliver K, Manna E, Collis P, King-Kallimanis BL et al (2023) The opportunity for greater patient and public involvement and engagement in drug development and regulation. Nat Rev Drug Discov 22:337\u2013338. https:\/\/doi.org\/10.1038\/d41573-023-00031-x","journal-title":"Nat Rev Drug Discov"},{"key":"1036_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/hex.12442","volume":"20","author":"B Wiering","year":"2017","unstructured":"Wiering B, de Boer D, Delnoij D (2017) Patient involvement in the development of patient-reported outcome measures: a scoping review. Health Expect 20:11\u201323. https:\/\/doi.org\/10.1111\/hex.12442","journal-title":"Health Expect"},{"key":"1036_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40271-016-0197-5","volume":"9","author":"KL Haywood","year":"2016","unstructured":"Haywood KL, Wilson R, Staniszewska S, Salek S (2016) Using PROMs in Healthcare: Who Should Be in the Driving Seat-Policy Makers, Health Professionals, Methodologists or Patients? Patient 9:495\u2013498. https:\/\/doi.org\/10.1007\/s40271-016-0197-5","journal-title":"Patient"},{"key":"1036_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12913-017-2582-8","volume":"17","author":"B Wiering","year":"2017","unstructured":"Wiering B, de Boer D, Delnoij D (2017) Patient involvement in the development of patient-reported outcome measures: The developers\u2019 perspective. BMC Health Serv Res 17:635. https:\/\/doi.org\/10.1186\/s12913-017-2582-8","journal-title":"BMC Health Serv Res"},{"key":"1036_CR8","doi-asserted-by":"publisher","unstructured":"Wilson R (2018) Patient led PROMs must take centre stage in cancer research. Res Involv Engagem 4. https:\/\/doi.org\/10.1186\/s40900-018-0092-4","DOI":"10.1186\/s40900-018-0092-4"},{"key":"1036_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41687-019-0172-8","volume":"4","author":"J Carlton","year":"2020","unstructured":"Carlton J, Peasgood T, Khan S, Barber R, Bostock J, Keetharuth AD (2020) An emerging framework for fully incorporating public involvement (PI) into patient-reported outcome measures (PROMs). J Patient Rep Outcomes 4:4. https:\/\/doi.org\/10.1186\/s41687-019-0172-8","journal-title":"J Patient Rep Outcomes"},{"key":"1036_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/hex.12459","volume":"20","author":"SJ Blackburn","year":"2017","unstructured":"Blackburn SJ (2017) Patient involvement vs. patient participation in qualitative research in the development of PROMs. Health Expect 20:371\u2013372. https:\/\/doi.org\/10.1111\/hex.12459","journal-title":"Health Expect"},{"key":"1036_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/0141076819890551","volume":"113","author":"G Turner","year":"2020","unstructured":"Turner G, Aiyegbusi OL, Price G, Skrybant M, Calvert M (2020) Moving beyond project-specific patient and public involvement in research. J R Soc Med 113:16\u201323. https:\/\/doi.org\/10.1177\/0141076819890551","journal-title":"J R Soc Med"},{"key":"1036_CR12","doi-asserted-by":"publisher","unstructured":"Cruz Rivera S, Stephens R, Mercieca-Bebber R, Retzer A, Rutherford C, Price G et al (2012) \u2018Give Us The Tools!\u2018: development of knowledge transfer tools to support the involvement of patient partners in the development of clinical trial protocols with patient-reported outcomes (PROs), in accordance with SPIRIT-PRO Extension. BMJ Open. 2021;11(6):e046450. https:\/\/doi.org\/10.1136\/bmjopen-2020-046450","DOI":"10.1136\/bmjopen-2020-046450"},{"key":"1036_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40900-018-0102-6","volume":"4","author":"N Doria","year":"2018","unstructured":"Doria N, Condran B, Boulos L, Curtis Maillet DG, Dowling L, Levy A (2018) Sharpening the focus: differentiating between focus groups for patient engagement vs. qualitative research. Res Involv Engagem 4:19. https:\/\/doi.org\/10.1186\/s40900-018-0102-6","journal-title":"Res Involv Engagem"},{"key":"1036_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40900-024-00587-x","volume":"10","author":"C Nollett","year":"2024","unstructured":"Nollett C, Eberl M, Fitzgibbon J, Joseph-Williams N, Hatch S (2024) Public involvement and engagement in scientific research and higher education: the only way is ethics? Res Involv Engagem 10:50. https:\/\/doi.org\/10.1186\/s40900-024-00587-x","journal-title":"Res Involv Engagem"},{"key":"1036_CR15","unstructured":"NHS Health Research Authority (2020) What do I need to do? https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/best-practice\/public-involvement\/what-do-i-need-do\/. Accessed 20 March 2025"},{"key":"1036_CR16","unstructured":"National Institute for Health and Care Research Blood and Transplant Research Unit in Precision Cellular Therapeutics https:\/\/www.rdm.ox.ac.uk\/about\/our-facilities-and-units\/nihr-btru-in-precision-cellular-therapeutics. Accessed 20 March 2025"},{"key":"1036_CR17","doi-asserted-by":"publisher","first-page":"e085392","DOI":"10.1136\/bmjopen-2024-085392","volume":"14","author":"SE Hughes","year":"2024","unstructured":"Hughes SE, McMullan C, Aiyegbusi OL, Shaw K, Kinsella F, Ferguson P et al (2024) Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (CAR-T) therapies (the PRO-CAR-T study). BMJ Open 14:e085392. https:\/\/doi.org\/10.1136\/bmjopen-2024-085392","journal-title":"BMJ Open"},{"key":"1036_CR18","unstructured":"Association of the British Pharmaceutical Industry (2024) Unlocking access to future ATMPs in the UK. https:\/\/www.abpi.org.uk\/publications\/unlocking-access-to-future-atmps-in-the-uk\/. Accessed 20 March 2025"},{"key":"1036_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jval.2019.03.014","volume":"22","author":"C Quinn","year":"2019","unstructured":"Quinn C, Young C, Thomas J, Trusheim M, Mit Newdigs FoCUS Writing Group (2019) Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System. Value Health 22:621\u2013626. https:\/\/doi.org\/10.1016\/j.jval.2019.03.014","journal-title":"Value Health"},{"key":"1036_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drudis.2021.09.001","volume":"27","author":"CM Young","year":"2022","unstructured":"Young CM, Quinn C, Trusheim M (2022) Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discov Today 27:17\u201330. https:\/\/doi.org\/10.1016\/j.drudis.2021.09.001","journal-title":"Drug Discov Today"},{"key":"1036_CR21","unstructured":"Alliance for Regenerative Medicine (2018) Annual regenerative medicine data report. https:\/\/alliancerm.org\/wp-content\/uploads\/2019\/03\/ARM_AR2018_Web_FINAL.pdf. Accessed 20 March 2025"},{"key":"1036_CR22","unstructured":"Alliance for Regenerative Medicine (2024) The sector snapshot: August 2024. https:\/\/alliancerm.org\/sector-snapshot-august-2024\/. Accessed 20 March 2025"},{"key":"1036_CR23","unstructured":"Economist Impact (2022) Cell and gene therapies. Health system progress in moving from cutting edge to common practice. https:\/\/impact.economist.com\/perspectives\/sites\/default\/files\/images\/ei223_cgt_methodology_paper_dv9.pdf. Accessed 20 March 2025"},{"key":"1036_CR24","unstructured":"Cell and Gene Therapy Catapult (2024) Annual Review 2024. Transforming healthcare with advanced therapies. https:\/\/cgt.ams3.cdn.digitaloceanspaces.com\/Cell-and-Gene-Therapy-Catapult-Annual-Review-2024.pdf. Accessed 20 March 2025"},{"key":"1036_CR25","doi-asserted-by":"crossref","unstructured":"Lilliu HL, Lee MK, Duole S, Rex M, Waeckel A, Famelart V, Pfizer (2022) A long-term forecast of the economic impact of gene therapies in France. https:\/\/www.ispor.org\/docs\/default-source\/euro2022\/a-long-term-forecast-of-the-economic-impact-of-gene-therapies-in-france-pdf.pdf. Accessed 20 March 2025","DOI":"10.1016\/j.jval.2022.09.1290"},{"key":"1036_CR26","doi-asserted-by":"publisher","first-page":"1200808","DOI":"10.3389\/fphar.2023.1200808","volume":"14","author":"S Bellino","year":"2023","unstructured":"Bellino S, La Salvia A, Cometa MF, Botta R (2023) Cell-based medicinal products approved in the European Union: current evidence and perspectives. Front Pharmacol 14:1200808. https:\/\/doi.org\/10.3389\/fphar.2023.1200808","journal-title":"Front Pharmacol"},{"key":"1036_CR27","doi-asserted-by":"publisher","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y (2023) CAR-T: What is next? Cancers (Basel)15. https:\/\/doi.org\/10.3390\/cancers15030663","DOI":"10.3390\/cancers15030663"},{"key":"1036_CR28","doi-asserted-by":"publisher","first-page":"105153","DOI":"10.1016\/j.healthpol.2024.105153","volume":"149","author":"Y Litvinova","year":"2024","unstructured":"Litvinova Y, Merkur S, Allin S, Angulo-Pueyo E, Behmane D, Bernal-Delgado E et al (2024) Availability and financing of CAR-T cell therapies: A cross-country comparative analysis. Health Policy 149:105153. https:\/\/doi.org\/10.1016\/j.healthpol.2024.105153","journal-title":"Health Policy"},{"key":"1036_CR29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bjh.18335","volume":"198","author":"L Shargian","year":"2022","unstructured":"Shargian L, Raanani P, Yeshurun M, Gafter-Gvili A, Gurion R (2022) Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis. Br J Haematol 198:838\u2013846. https:\/\/doi.org\/10.1111\/bjh.18335","journal-title":"Br J Haematol"},{"key":"1036_CR30","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","volume":"4","author":"D Sermer","year":"2020","unstructured":"Sermer D, Batlevi C, Palomba ML, Shah G, Lin RJ, Perales MA et al (2020) Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv 4:4669\u20134678. https:\/\/doi.org\/10.1182\/bloodadvances.2020002118","journal-title":"Blood Adv"},{"key":"1036_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ (2019) The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. Am Soc Clin Oncol Educ Book 39:433\u2013444. https:\/\/doi.org\/10.1200\/EDBK_238691","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1036_CR32","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN (2023) How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141:2430\u20132442. https:\/\/doi.org\/10.1182\/blood.2022017414","journal-title":"Blood"},{"key":"1036_CR33","unstructured":"NHS Blood and Transplant\/UK Stem Cell Strategic Forum (2022) A 10 year vision for stem cell transplantation and cellular therapies. Innovative, transformational, sustainable. https:\/\/nhsbtdbe.blob.core.windows.net\/umbraco-assets-corp\/28283\/a-10-year-vision-for-hsct-and-cellular-therapies-august-2022-8.pdf. Accessed 20 March 2025"},{"key":"1036_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/d41586-024-01215-0","volume":"629","author":"C Willyard","year":"2024","unstructured":"Willyard C (2024) Do cutting-edge CAR-T-cell therapies cause cancer? What the data say. Nature 629:22\u201324. https:\/\/doi.org\/10.1038\/d41586-024-01215-0","journal-title":"Nature"},{"key":"1036_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41409-024-02248-9","volume":"59","author":"JR Passweg","year":"2024","unstructured":"Passweg JR, Baldomero H, Ciceri F, de la Camara R, Glass B, Greco R et al (2024) Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transpl 59:803\u2013812. https:\/\/doi.org\/10.1038\/s41409-024-02248-9","journal-title":"Bone Marrow Transpl"},{"key":"1036_CR36","unstructured":"Brigden T (2024) Regulating ATMPs in the UK after Brexit. https:\/\/www.phgfoundation.org\/wp-content\/uploads\/2024\/10\/Regulating-Advanced-Therapy-Medicinal-Products-in-the-UK-after-Brexit.pdf. Accessed 20 March 2025"},{"key":"1036_CR37","unstructured":"World Health Organization (2024) WHO considerations in developing a regulatory framework for human cells and tissues and for advanced therapy medicinal products. Executive summary of WHO Implementation workshop, Muscat, Oman, 14\u201316 May 2024. https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/biotherapeutics\/executive-summary_who-cgtp-workshop_oman_web-post_9-july-2024.pdf?sfvrsn=6ae41781_1&download=true. Accessed 20 March 2025"},{"key":"1036_CR38","unstructured":"European Medicine Agency; European Organisation for Research and Treatment of Cancer (2024) How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions? https:\/\/www.ema.europa.eu\/en\/events\/ema-european-organisation-research-treatment-cancer-eortc-workshop-how-can-patient-reported-outcomes-pro-health-related-quality-life-hrqol-data-inform-regulatory-decisions#:~:text=Live%20broadcast-,Event%20summary,stakeholders%20aiming%20at%20international%20collaboration Accessed 20 March 2025"},{"key":"1036_CR39","doi-asserted-by":"publisher","first-page":"111617","DOI":"10.1016\/j.jclinepi.2024.111617","volume":"178","author":"A Ciuca","year":"2025","unstructured":"Ciuca A, Banka S, Clancy T, Jones S, Kirkham JJ, Newman WG et al (2025) Patient-reported outcomes and measures are under-utilised in advanced therapy medicinal products trials for orphan conditions. J Clin Epidemiol 178:111617. https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111617","journal-title":"J Clin Epidemiol"},{"key":"1036_CR40","doi-asserted-by":"publisher","unstructured":"Messina AJ, Andrianov V, Mazzolenis D, Vidal-Fisher L (2020) Emerging trends and utilization of patient-reported outcomes (PROs) in clinical trials of chimeric antigen receptor (CAR) T-cell therapies. J Clin Oncol 38. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e1914","DOI":"10.1200\/JCO.2020.38.15_suppl.e1914"},{"key":"1036_CR41","doi-asserted-by":"publisher","unstructured":"Taylor S, Law K, Coomber-Moore J, Davies M, Thistlewaite F, Calvert M et al (2023) Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review. Syst Rev-London 12. https:\/\/doi.org\/10.1186\/s13643-023-02337-8","DOI":"10.1186\/s13643-023-02337-8"},{"key":"1036_CR42","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s11136-024-03728-7","volume":"33","author":"M Anderson","year":"2024","unstructured":"Anderson M, van Kessel R, Wood E, Stokes A, Fistein J, Porter I et al (2024) Understanding factors impacting patient-reported outcome measures integration in routine clinical practice: an umbrella review. Qual Life Res 33:2611\u20132629. https:\/\/doi.org\/10.1007\/s11136-024-03728-7","journal-title":"Qual Life Res"},{"key":"1036_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-024-02827-9","volume":"30","author":"OL Aiyegbusi","year":"2024","unstructured":"Aiyegbusi OL, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N et al (2024) Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med 30:650\u2013659. https:\/\/doi.org\/10.1038\/s41591-024-02827-9","journal-title":"Nat Med"},{"key":"1036_CR44","unstructured":"PROTEUS (2023) The PROTEUS guide to implementing patient-reported outcomes in clinical practice: a synthesis of resources. Prepared by Crossnohere N, Brundage M, Snyder C, and the Advisory Group. https:\/\/theproteusconsortium.org\/proteus-practice\/proteus-practice-guide\/. Accessed 20 March 2025"},{"key":"1036_CR45","unstructured":"US Food and Drugs Administration (2022) Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome. Accessed 20 March 2025"},{"key":"1036_CR46","unstructured":"US Food and Drugs Administration (2022) Patient-focused drug development: methods to identify what is important to patients. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed 20 March 2025"},{"key":"1036_CR47","unstructured":"Snyder C, Wu AW (eds) (2017) Users\u2019 guide to integrating patient-reported outcomes in electronic health records. Baltimore, MD: Johns Hopkins University. Funded by patient-centered outcomes research institute (PCORI); JHU contract No. 10.01.14 TO2 08.01.15. https:\/\/www.pcori.org\/document\/users-guide-integrating-patient-reported-outcomes-electronic-health-records. Accessed 20 March 2025"},{"key":"1036_CR48","unstructured":"UK Public Involvement Standards Development Partnership (2019) UK standards for public involvement in research. Better public involvement for better health and social care research. https:\/\/sites.google.com\/nihr.ac.uk\/pi-standards\/home. Accessed 20 March 2025"},{"key":"1036_CR49","doi-asserted-by":"publisher","first-page":"n434","DOI":"10.1136\/bmj.n434","volume":"372","author":"S Redman","year":"2021","unstructured":"Redman S, Greenhalgh T, Adedokun L, Staniszewska S, Denegri S (2021) Co-production of Knowledge Collection Steering C. Co-production of knowledge: the future. BMJ 372:n434. https:\/\/doi.org\/10.1136\/bmj.n434","journal-title":"BMJ"},{"key":"1036_CR50","doi-asserted-by":"publisher","unstructured":"National Institute for Health and Care Research Blood and Transplant Research Unit in Precision Cellular Therapeutics (2022) Patient and public involvement and engagement strategy, 2022\u20132027. Birmingham: University of Birmingham. https:\/\/doi.org\/10.48352\/uobxbtru.0002. Accessed 20 March 2025","DOI":"10.48352\/uobxbtru.0002"},{"key":"1036_CR51","doi-asserted-by":"publisher","unstructured":"National Institute for Health and Care Research Blood and Transplant Research Unit in Precision Cellular Therapeutics (2023) Patient and public involvement and engagement delivery plan, 2022\u20132027. Birmingham: University of Birmingham. https:\/\/doi.org\/10.48352\/uobxbtru.0001. Accessed 20 March 2025","DOI":"10.48352\/uobxbtru.0001"},{"key":"1036_CR52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40900-023-00424-7","volume":"9","author":"A De Simoni","year":"2023","unstructured":"De Simoni A, Jackson T, Inglis Humphrey W, Preston J, Mah H, Wood HE et al (2023) Patient and public involvement in research: the need for budgeting PPI staff costs in funding applications. Res Involv Engagem 9:16. https:\/\/doi.org\/10.1186\/s40900-023-00424-7","journal-title":"Res Involv Engagem"},{"key":"1036_CR53","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2217\/rme-2020-0181","volume":"16","author":"K Macpherson","year":"2021","unstructured":"Macpherson K, Aiyegbusi OL, Elston L, Myles S, Washington J, Sungum N et al (2021) A scoping review of patient and public perspectives on cell and gene therapies. Regen Med 16:1005\u20131017. https:\/\/doi.org\/10.2217\/rme-2020-0181","journal-title":"Regen Med"},{"key":"1036_CR54","unstructured":"National Institute for Health and Care Research (2024) Payment guidance for researchers and professionals involving people in research. https:\/\/www.nihr.ac.uk\/payment-guidance-researchers-and-professionals. Accessed 20 March 2025"},{"key":"1036_CR55","unstructured":"National Institute for Health and Care Research (2021) Public Information Pack: How to get involved in NHS, public health and social care research. https:\/\/www.nihr.ac.uk\/public-information-pack-how-get-involved-nhs-public-health-and-social-care-research. Accessed 20 March 2025"},{"key":"1036_CR56","doi-asserted-by":"publisher","unstructured":"National Institute for Health and Care Research Blood and Transplant Research Unit in Precision Cellular Therapeutics (2023) Public and patient involvement and engagement (PPIE). A practical planning guide for BTRU researchers. Birmingham: University of Birmingham. https:\/\/doi.org\/10.48352\/uobxbtru.0003. Accessed 20 March 2025","DOI":"10.48352\/uobxbtru.0003"},{"key":"1036_CR57","unstructured":"Newman AM, McAlister B, Seddon K, Peddle S, Nelson A (2023) Public involvement in research impact toolkit (PIRIT). Cardiff: Cardiff University. https:\/\/www.cardiff.ac.uk\/marie-curie-research-centre\/patient-and-public-involvement\/public-involvement-in-research-impact-toolkit-pirit. Accessed 20 March 2025"},{"key":"1036_CR58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","volume":"17","author":"SC Rivera","year":"2019","unstructured":"Rivera SC, Kyte DG, Aiyegbusi OL, Slade AL, McMullan C, Calvert MJ (2019) The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis. Health Qual Life Outcomes 17:156. https:\/\/doi.org\/10.1186\/s12955-019-1220-z","journal-title":"Health Qual Life Outcomes"},{"key":"1036_CR59","unstructured":"All Ireland Institute of Hospice and Palliative Care (2017) Evidence-based Model for the exchange and Transfer of Research Knowledge (EMTReK). https:\/\/aiihpc.org\/our_work\/research\/knowledge-transfer\/. Accessed 20 March 2025"},{"key":"1036_CR60","doi-asserted-by":"publisher","first-page":"e476","DOI":"10.1016\/S1470-2045(24)00256-0","volume":"25","author":"F Khatsuria","year":"2024","unstructured":"Khatsuria F, McMullan C, Aiyegbusi OL, Shaw KL, Iqbal R, Kinsella F et al (2024) Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies. Lancet Oncol 25:e476\u2013e88. https:\/\/doi.org\/10.1016\/S1470-2045(24)00256-0","journal-title":"Lancet Oncol"},{"key":"1036_CR61","doi-asserted-by":"publisher","first-page":"103256","DOI":"10.1016\/j.eclinm.2025.103256","volume":"84","author":"SE Hughes","year":"2025","unstructured":"Hughes SE, Khatsuria F, McMullan C, Shaw KL, Walker A, Kinsella F et al (2025) Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study. EClinMed 84:103256. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103256","journal-title":"EClinMed"},{"key":"1036_CR62","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S1470-2045(24)00644-2","volume":"26","author":"K Lapen","year":"2025","unstructured":"Lapen K, Feliciano EJG, Dee EC, Gillespie EF, Yahalom J, Imber BS (2025) Electronic patient-reported outcomes for CAR T-cell therapies. Lancet Oncol 26:e6. https:\/\/doi.org\/10.1016\/S1470-2045(24)00644-2","journal-title":"Lancet Oncol"},{"key":"1036_CR63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40900-024-00617-8","volume":"10","author":"J Garcia-Iglesias","year":"2024","unstructured":"Garcia-Iglesias J, Beange I, Davidson D, Goopy S, Huang H, Murray F et al (2024) Ethical considerations in public engagement: developing tools for assessing the boundaries of research and involvement. Res Involv Engagem 10:83. https:\/\/doi.org\/10.1186\/s40900-024-00617-8","journal-title":"Res Involv Engagem"},{"key":"1036_CR64","unstructured":"Health Research Authority; Medical Research Council (2022) HRA Decision Tool. https:\/\/www.hra-decisiontools.org.uk\/research\/. Accessed 20 March 2025"},{"key":"1036_CR65","unstructured":"Hanley B, Staley K, Stewart D, Barber R (2019) Qualitative research and patient and public involvement in health and social care research: What are the key differences? https:\/\/www.learningforinvolvement.org.uk\/content\/resource\/qualitative-research-and-patient-and-public-involvement-in-health-and-social-care-research-what-are-the-key-differences\/. Accessed 20 March 2025"},{"key":"1036_CR66","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40900-019-0169-8","volume":"5","author":"I Muller","year":"2019","unstructured":"Muller I, Santer M, Morrison L, Morton K, Roberts A, Rice C et al (2019) Combining qualitative research with PPI: reflections on using the person-based approach for developing behavioural interventions. Res Involv Engagem 5:34. https:\/\/doi.org\/10.1186\/s40900-019-0169-8","journal-title":"Res Involv Engagem"},{"key":"1036_CR67","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41591-022-01781-8","volume":"28","author":"MJ Calvert","year":"2022","unstructured":"Calvert MJ, Cruz Rivera S, Retzer A, Hughes SE, Campbell L, Molony-Oates B et al (2022) Patient reported outcome assessment must be inclusive and equitable. Nat Med 28:1120\u20131124. https:\/\/doi.org\/10.1038\/s41591-022-01781-8","journal-title":"Nat Med"},{"key":"1036_CR68","unstructured":"National Institute for Health and Care Research (2022) NIHR Public Involvement Feedback Survey 2020\u20132021: The results. https:\/\/www.nihr.ac.uk\/nihr-public-involvement-feedback-survey-2020-2021-results#:~:text=79%25%20of%20respondents%20stated%20they,had%20sometimes%20made%20a%20difference. Accessed 20 March 2025"},{"key":"1036_CR69","unstructured":"National Institute for Health and Care Research (2023) Race Equality Framework for Public Involvement in Research. https:\/\/www.nihr.ac.uk\/nihr-race-equality-framework. Accessed 30 Sept 2025"},{"key":"1036_CR70","doi-asserted-by":"publisher","unstructured":"Retzer A, Ciytak B, Khatsuria F, El-awaisi J, Harris IM, Chapman L et al (2023) A toolkit for capturing a representative and equitable sample in health research. Nat Med 29:3259\u20133267. https:\/\/doi.org\/10.1038\/s41591-023-02665-1","DOI":"10.1038\/s41591-023-02665-1"},{"key":"1036_CR71","volume-title":"Getting our house in order: improving conditions for co-produced research in UK higher education. Introducing the Co-Production Futures Inquiry. Briefing Note 1","author":"B Perry","year":"2024","unstructured":"Perry B, Durose C, Richardson L (2024) Getting our house in order: improving conditions for co-produced research in UK higher education. Introducing the Co-Production Futures Inquiry. Briefing Note 1. Universities of Liverpool, Manchester and Sheffield"},{"key":"1036_CR72","unstructured":"National Institute for Health and Care Research (2022) Funding for community research partnerships. https:\/\/www.nihr.ac.uk\/funding-community-research-partnerships-information-pack-community-or-charity-organisations-and-groups. Accessed 20 March 2025"},{"key":"1036_CR73","volume-title":"The Co-Production Futures Inquiry: Response to the Call for Evidence and Ideas. Briefing Note 2","author":"B Vince-Myers","year":"2025","unstructured":"Vince-Myers B (2025) The Co-Production Futures Inquiry: Response to the Call for Evidence and Ideas. Briefing Note 2. Universities of Liverpool, Manchester and Sheffield"},{"issue":"5","key":"1036_CR74","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/hex.12486","volume":"20","author":"A Gibson","year":"2017","unstructured":"Gibson A, Welsman J, Britten N (2017) Evaluating patient and public involvement in health research: from theoretical model to practical workshop. Health Expect 20(5):826\u2013835","journal-title":"Health Expect"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01036-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01036-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01036-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:20:19Z","timestamp":1777602019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01036-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01036-x","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable: The manuscript includes views of Public Contributors, as part of our Patient and Public Involvement and Engagement (PPIE). Research ethics was not required, as Public Contributors are deemed collaborators rather than research participants. However, a favourable research ethics committee approval was given for the study described, which detailed the role of PPIE (Health and Social Care Research Ethics Committee B (REC B), Reference: 23\/NI\/0104).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable: No personal data is included, other than anonymous quotes given by Public Contributors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OLA receives funding from the National Institute for Health and Care Research (NIHR) Birmingham Biomedical research Centre (BRC), West Midlands, Birmingham, NIHR Applied Research Collaboration (ARC) West Midlands, NIHR Blood and Transplant Research Unit in Precision Cellular Therapeutics (BTRU-PCT), LifeArc, UK Research and Innovation (UKRI), Health Foundation, Merck, Anthony Nolan, Gilead Sciences Ltd, Sarcoma UK, and GSK. He declares personal fees from Gilead Sciences Ltd, Merck and GSK outside the submitted work. MC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for the Centre for Patient Reported Outcomes Research and is a NIHR Senior Investigator. MC receives funding from the NIHR, UKRI, NIHR Birmingham BRC, NIHR BTRU-PCT, LifeArc, the NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR ARC West Midlands, UK SPINE, European Regional Development Fund \u2013 Demand Hub and Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB Pharma, Merck, Anthony Nolan, GSK and Gilead. MC has received personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI), Genentech, Vertex, ICON, Halfloop, and Pfizer outside the submitted work. In addition, a family member owns shares in GSK. RC receives funding from NIHR BTRU-PCT and Oxford NIHR BRC. RC is on the Advisory Board of Novartis and Accelerating Clinical Trials Ltd and has received consulting fees for Accelerating Clinical Trials Ltd and speaking honoraria from Miltenyi and Malinkrodt Pharmaceuticals. SEH receives funding from the NIHR, UKRI, Rinri Therapeutics, Anthony Nolan, and declares personal fees from Cochlear Ltd, Astra Zeneca, Pfizer, CIS Oncology, and Aparito Ltd outside the submitted work. CM receives funding from NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC), UKRI, CIS Oncology, Anthony Nolan, and declares personal fees from Aparito Ltd outside the submitted work. KLS receives funding from NIHR BTRU-PCT. VY receives funding from NIHR BTRU-PCT. Other authors have declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}